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SUMMARY
Growing evidence supports the importance of gut microbiota in the control of tumor growth and 
response to therapy. Here, we select prebiotics that can enrich bacterial taxa that promote anti-
tumor immunity. Addition of the prebiotics inulin or mucin to the diet of C57BL/6 mice induces 
anti-tumor immune responses and inhibition of BRAF mutant melanoma growth in a 
subcutaneously implanted syngeneic mouse model. Mucin fails to inhibit tumor growth in germ-
free mice, indicating that the gut microbiota is required for the activation of the anti-tumor 
immune response. Inulin and mucin drive distinct changes in the microbiota, as inulin, but not 
mucin, limits tumor growth in syngeneic mouse models of colon cancer and NRAS mutant 
melanoma and enhances the efficacy of a MEK inhibitor against melanoma while delaying the 
emergence of drug resistance. We highlight the importance of gut microbiota in anti-tumor 
immunity and the potential therapeutic role for prebiotics in this process.
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In Brief
Li et al. show that the gut microbiota effect on anti-tumor immunity is affected by inulin or mucin, 
prebiotics that inhibit melanoma and colon cancer growth in syngeneic models and attenuate 
melanoma resistance to MEKi. These studies highlight a potential therapeutic role for prebiotics in 
shaping the microbiota composition to promote anti-tumor immunity.
INTRODUCTION
Melanoma remains one of the most aggressive tumor types, mainly because of its propensity 
to metastasize and resist therapy. Aberrant activation of the mitogen-activated protein kinase 
(MAPK) pathway has been reported in human BRAF and NRAS mutant tumors, including 
melanomas, in which they account for more than 70% of genetic changes. Although 
selective inhibitors to BRAF mutant proteins have been developed, their effectiveness is 
limited by the frequent emergence of resistance (Brighton et al., 2018; Fedele et al., 2018; 
Martz et al., 2014). Inhibitors of the MAPK pathway, including MEK, have also been 
developed and are commonly used for the treatment of NRAS mutant melanomas (Johnson 
and Puzanov, 2015). The emergence of immune checkpoint therapy has resulted in 
unprecedented clinical success and offered new therapeutic modalities (Colli et al., 2017; 
Eggermont et al., 2018; Ribas et al., 2019). At present, BRAF inhibitors (BRAFi) and MEK 
inhibitors (MEKi) are being tested in several clinical trials, in combination with other 
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therapies, including immune checkpoint inhibitors and gut microbiota modulators 
(Humphries and Daud, 2018; Matson et al., 2018; York, 2018).
The gastrointestinal (GI) tract harbors a complex and dynamic population of bacteria, called 
gut microbiota, that are implicated in the maintenance of health and the onset and 
progression of disease (Sommer and Bäckhed, 2013). In these roles, gut microbiota affect 
key components of host physiology and homeostasis, including the development and 
function of the immune system (Bäckhed et al., 2005; Ley et al., 2008). Changes in gut 
microbiota composition are linked to local and systemic alterations that affect tumor growth, 
in part through modulation of tissue remodeling, mucosal immunity, and anti-tumor 
immunity (Rutkowski et al., 2015). Gut microbiota also influence the incidence and 
progression of colorectal carcinoma (Arthur et al., 2012; Bonnet et al., 2014) and breast and 
hepatocellular carcinoma (Arthur et al., 2012; Dapito et al., 2012). The importance of gut 
microbiota composition in cancer (Adolph et al., 2013) has been further demonstrated in 
studies showing the ability of the microbiota to enhance responses to checkpoint inhibitors 
such as anti-PD-(L)1 antibodies (Gopalakrishnan et al., 2018b; Haapanen et al., 1997; 
Matson et al., 2018; Sivan et al., 2015) and anti-CTLA-4 antibodies (Chaput et al., 2017; 
Vétizou et al., 2015). Furthermore, bacterial commensals that were found to be more 
abundant in the gut of melanoma patients responding to anti-PD-1 therapy (Gopalakrishnan 
et al., 2018b; Haapanen et al., 1997; Matson et al., 2018; Sivan et al., 2015), provided a 
rationale for performing fecal microbiota transplantation to non-responding patients.
Despite their clinical efficacy, checkpoint inhibitors are effective in only a fraction of treated 
patients. Human fecal microbiota derived from therapy-responsive patients confer treatment 
responsiveness when transplanted into germ-free (GF) mice (Matson et al., 2018; Routy et 
al., 2018), while a small set of phylogenetically unrelated gut microbiota species was 
suggested to promote anti-tumor phenotypes. For example, introduction of Bacteroides 
thetaiotaomicron or Bacteroides fragili to GF mice was sufficient to restore anti-tumor 
responses via induction of a skewed Th1 response (Vétizou et al., 2015). Our recent study 
demonstrated that Bacteroides rodentium induced anti-tumor immunity in melanoma and 
colon cancer models that were subcutaneously implanted in syngeneic C57BL/6 mice (Li et 
al., 2019b). In another study, the abundance of Akkermansia muciniphila was associated 
with anti-PD-1 responsiveness in humans and restored an anti-tumor phenotype when co-
administered with anti-PD-1 therapy to melanoma patients (Routy et al., 2018). 
Administration of Bifidobacterium spp. in combination with anti-PD-L1 agents, attenuated 
tumor growth and promoted anti-tumor immunity in a syngeneic mouse model (Sivan et al., 
2015). Moreover, human melanoma patients who responded to anti-CTLA-4 (ipilimumab) 
were found to have gut microbiota enriched in three butyrate-producing bacterial species 
(Chaput et al., 2017), and administration of Enterococcus hirae and Barnesiella 
intestinihominis improved their response to cyclophosphamide chemotherapy (Daillère et 
al., 2016). An assessment of mice treated with various antibiotics revealed that ampicillin-
treated mice retained a simplified microbiota with a potent anti-tumor phenotype (Tanoue et 
al., 2019). Isolates from these mice identified 11 strains, enriched in Bacteroides, 
Parabacteroides, Alistipes, and an uncharacterized Ruminococcaceae, that increased the 
abundance of CD8+ interferon-γ (IFN-γ)-producing cells in the gut and potentiated anti-
PD-1- and anti-CTLA-4-mediated control of tumor growth. Collectively, these findings point 
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to the importance of gut microbiota in controlling cancer growth and reveal the complex 
variety of species that can promote anti-tumor immunity.
Previous reports indicated that the prebiotic inulin increases the relative abundance of 
Bifidobacteria, Bacteroides, and Akkermansia muciniphila in mice (Everard et al., 2013; 
Fehlbaum et al., 2018; Li et al., 2019a; Singh et al., 2018). Among these, Akkermansia 
muciniphila is known to reside in the mucin layer of the GI tract, in which it consumes 
glycan substrates decorating mucin proteins (muc2). Our earlier studies identified 
microbiota-dependent anti-melanoma immunity in syngeneic Rnf5−/− mice, which was 
conferred by select bacterial strains that induced tumor infiltration by T cells and dendritic 
cells (DCs) and inhibited melanoma growth upon their inoculation in GF mice (Li et al., 
2019b).
The prebiotics inulin and mucin have been reported to induce Bifidobacterium spp. and 
Akkermansia muciniphila (Everard et al., 2013; Fehlbaum et al., 2018; Li et al., 2019a; 
Singh et al., 2018). Cultivation of fecal samples with inulin and mucin increased the relative 
abundance of several species implicated in tumor growth control in the Rnf5−/− mice (Li et 
al., 2019b). Therefore, in this study, we investigated the effects of inulin and porcine gastric 
mucin on growth of a subcutaneously implanted tumor and its propensity to resist targeted 
therapy in syngeneic mouse models. We demonstrate the ability of these prebiotics to elicit 
changes in gut microbiota composition that play a pivotal role in eliciting effective anti-
tumor immunity.
RESULTS
Prebiotic Treatment of Fecal Microbiota In Vitro Enriches for Taxa that Promote Anti-tumor 
Immunity
Inulin and mucin have been shown to alter the relative abundance of bacterial species that 
were identified as anti-tumor immunity-promoting bacteria in Rnf5−/−mice, including 
Parasutterella excrementihominis, Bacteroides rodentium, and Clostridium viride (Figures 
S1A and S1B). We thus tested the effect of inulin and mucin on anaerobic cultivation of 12 
fecal samples derived from healthy human subjects. Both prebiotics increased the relative 
abundance of Bacteroides spp., whereas only mucin increased the relative abundance of 
Akkermansia muciniphila in most cultures (Figure S1C). Surprisingly, inulin, but not mucin, 
promoted the growth of Bifidobacteria spp. in only two of the cultures.
Feeding of Mucin or Inulin to Wild-Type Mice Reduces Tumor Growth and Induces Anti-
tumor Immunity
Inulin is a naturally occurring fructosyl polymer with chain-terminating glucosyl residues. 
Mucins are highly decorated with polysaccharides composed of various core structures 
similar to those found in Lewis blood type antigens, including the sugars galactose, fucose, 
sialic acid, galactosamine, glucosamine, and mannose. To determine whether prebiotics 
inhibit tumor growth, mucin (3% in drinking water) or inulin (15% w/w in chow) were 
administered to wild-type (WT) C57BL/6 mice starting 2 weeks before subcutaneous 
injection of syngeneic melanoma tumor cells (YUMM1.5 cells, 1 × 106 cells/mouse) 
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through the remainder of the experiment. Administration of mucin or inulin led to attenuated 
melanoma tumor growth (Figure 1A). To determine whether these changes could be 
attributed to anti-tumor immunity, we analyzed tumor-infiltrating lymphocytes (TILs) 20 
days following tumor inoculation. Compared with control mice, tumors from mucin- or 
inulin-treated mice were enriched in CD45+ cells, including effector (CD44hi) CD4+ and 
CD8+ T cells (e.g., IFN-γ-producing CD4+ T cells), plasmacytoid DCs, and conventional 
CD8α+ DCs (Figures 1B–1D). Tumor-resident DCs isolated from inulin- or mucin-treated 
C57BL/6 mice expressed higher levels of major histocompatibility complex (MHC) class I 
and MHC class II (Figure 1E), implying greater stimulatory capacity, compared with the 
tumor-associated cells from control mice. These data indicate that prebiotic supplementation 
induced a shift to a proinflammatory tumor microenvironment associated with a more potent 
anti-tumor response. The immunomodulatory effects of the two prebiotics were largely 
overlapping, but not identical, yet had similar effects on tumor control. Antibody-mediated 
depletion of CD4+ and CD8+ T cells in inulin-treated mice (Figure 1F) reduced the 
suppression of tumor growth, pointing to an essential role for CD4+ and CD8+ T cells in the 
inulin-promoted anti-tumor phenotype.
Mucin and Inulin Feeding Enhances Expression of Anti-tumor Immunoregulatory Genes in 
Tumors
To identify possible mechanisms for the elevated immune cell infiltration and anti-tumor 
immunity in prebiotic-treated mice, we examined tumor-xenograft samples grown in 
syngeneic mouse models for changes in the transcription of immune-associated genes 
(including chemokines), inflammasome activity, and antigen presentation. Both prebiotics 
increased the expression of chemokines (CCL4 and CCL8), inflamma-some-related genes 
(TLR3 and TLR7), and antigen presentation-related genes (CD40, Stat1, and ICOS) (Figure 
2A), suggesting a mechanism by which prebiotic supplementation enhanced the recruitment 
and activation of immune cells in the tumor microenvironment.
Independent support for the activation of T cells in prebiotic-treated mice was obtained 
using the OVA-specific OT-I transgenic mouse model. WT OT-I CD8+ CD45.1+ T cells were 
transferred to untreated or mucin-treated WT mice harboring B16F10-OVA melanoma 
tumors, and their frequency in tumor-draining and non-draining lymph nodes was 
monitored. OT-I CD8+ T cells were more abundant in the draining lymph nodes of mucin-
treated mice compared with control mice (Figures 2B and S2A), pointing to either increased 
recruitment or increased survival of OT-1 cells in the prebiotic-treated mice. Altogether, 
these results confirm that prebiotic treatment promotes anti-tumor immunity via effects on 
both innate and adaptive immune cells.
Consistent with the elevated abundance of TILs in mucin-treated compared with control 
C57BL/6 mice, levels of the cytokine interleukin (IL)-1α and chemokine CXCL13 were 
increased in the sera of mucin-fed mice before tumor cell inoculation (Figure 2C), 
suggesting that the inflammation-promoting effects of mucin were systemic. Strikingly, we 
found that mucin-treated tumor-xenograft-bearing mice exhibited reduced serum levels of 
IL-6, IL-1α, IL-10, IL-17A, and IL-23 compared with control animals (Figure 2D). High 
serum levels of IL-6 and IL-17 were previously associated with poor clinical outcome 
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(Rutkowski et al., 2015; Wang et al., 2009), whereas reduced IL-1α levels were associated 
with attenuated tumor growth (Apte et al., 2006). Lower serum levels of the chemokines 
CXCL1 and CXCL13 were also found in mucin-treated mice compared with control mice 
(Figure S2B), linking levels of both chemokines and cytokines with the anti-tumor response.
Inulin and Mucin Alter Gut Microbiota
We next used 16S rRNA amplicon sequencing to profile the fecal microbiota of WT 
C57BL/6 mice before and 14 days after prebiotic feeding and 20 days after YUMM1.5 
tumor cell inoculation, with tumor cells originally obtained from genetically engineered 
C57BL/6 mice harboring BrafV600E mutation, Pten deletion, and Cdkn2a deletion. Although 
the bacterial communities at baseline were heterogeneous and generally not well clustered 
(Figures 3A and 3B), prebiotic feeding resulted in the formation of more highly related 
communities that were distinct from those in control mice. Furthermore, the bacterial 
communities underwent additional restructuring following tumor cell inoculation. These 
data are consistent with recent observations that distal tumor growth results in a 
reconfiguration of gut microbiota (Li et al., 2019b). Individual phylotype groups (two or 
more highly related, but not identical, 16S sequences of strains approximating a species) that 
were altered in the microbiota of control and prebiotic-treated mice were identified but were 
not further assessed. Thus, only phylotypes that were associated with a specific prebiotic 
treatment were further studied.
Sequencing of the amplified 16S V3-V4 region followed by computational analysis led to 
the identification of increased relative abundance of 17 phylotype groups in inulin-treated 
mice and 2 phylotype groups in the mucin-treated mice that were not present in control mice 
(Table S1). Inulin increased the relative abundance of taxa that were phylogenetically 
coherent, 66% of which mapped most closely to members of Clostridium cluster XIVa, 
primarily Clostridium populeti- and Clostridium saccharolyticum-related taxa (Table S1). 
Although this cluster consists of numerous butyrate producers, the phylogenetic distance of 
the phylotypes profiled here makes the butyrate-producing potential of these taxa uncertain. 
Among the phylotypes that displayed increased relative abundance following inulin 
treatment, six were negatively correlated with tumor size (Figure 3C). Mucin also 
predominantly enriched taxa with similarity to members of Clostridium cluster XIVa (Table 
S1); however, none of the phylotypes induced by mucin were negatively correlated with 
tumor size. These findings suggest that inulin and mucin drive distinct changes in gut 
microbiota, both of which are capable of inducing anti-tumor immunity.
Inulin Attenuates Colon Cancer Growth
We next assessed whether mucin or inulin supplementation affects the growth of tumor types 
other than melanoma. Using the same protocol (prebiotic feeding starting 2 weeks before 
tumor inoculation), we found that inulin, but not mucin, attenuated the growth of 
subcutaneously transplanted MC-38 colon cancer tumors in syngeneic C57BL/6 mice 
(Figure 4A) and enhanced the anti-tumor immune response, as reflected by increased MHC 
class I and MHC class II expression on DCs (Figure 4B). No differences in the abundance of 
CD4+ or CD8+ T cells, total CD45+ cells, DCs, or DC subsets or the production of cytokines 
were observed in tumors from mucin- or inulin-treated mice (Figure S3). Although both 
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mucin and inulin induced anti-tumor immunity that limited the growth of melanoma tumors, 
only inulin was able to attenuate colon cancer growth. Thus, the differences in taxa induced 
by these prebiotics may account for their distinct effects on control of select tumor types.
Specific Microbiota Are Associated with Control of Colon Cancer Growth and Anti-tumor 
Immunity
Analysis of fecal microbiota from MC-38 tumor-bearing inulin- or mucin-treated mice 
indicated that both prebiotics increased the relative abundance of a similar number of 
phylotype groups (25 inulin and 21 mucin), of which 7 were common to both prebiotics 
(Table S2). More than 68% of the phylotype groups induced by inulin mapped to 
Clostridium cluster XIVa, compared with 33% induced by mucin. Additional analysis 
demonstrated that the relative abundance of six inulin-specific phylotypes was inversely 
correlated with MC-38 tumor size (Figure 4C), whereas no relationship with tumor size was 
detected for the phylotype groups induced by mucin.
Combination Treatment with Inulin Overcomes Melanoma Resistance to MEKi
We next determined whether prebiotic supplementation influenced the efficacy of MEKi 
treatment by examining growth of the N-RAS mutant mouse melanoma cell line MaN-RAS 
that was obtained from genetically engineered N-Ras melanoma grown in C57BL/6 mice. 
Syngeneic mice (C57BL/6) were subcutaneously inoculated with tumor cells 2 weeks after 
the initiation of feeding with inulin or mucin with or without MEKi. In the absence of 
MEKi, inulin, but not mucin, modestly controlled tumor growth (Figure 5A). However, co-
administration of MEKi with inulin had an additive effect on tumor growth control, and the 
emergence of MEKi resistance was delayed compared with MEKi alone (Figure 5A), 
implying that MEKi resistance may be partially overcome by this prebiotic. Consistent with 
these findings, tumors from mice treated with inulin+MEKi contained elevated numbers of 
total CD45+ cells, CD4+ and CD8+ T cells, pDCs, and mDCs, and the DCs expressed 
elevated levels of MHC class I compared with mice treated with MEKi alone (Figures 5B 
and 5C). However, no differences in T cell-mediated cytokine production were detected in 
tumors from inulin+MEKi-treated mice (Figure S4A).
Inulin-Induced Alterations in Gut Microbiota Control NRAS Mutant Melanoma Tumor 
Growth and MEKi Resistance
Inulin and mucin treatment before MEKi injection increased the relative abundance of 39 
and 23 phylotype groups, respectively (Figures 5D, S4B, and S4C), and the abundance of 
these groups was negatively correlated with tumor size (Figures S4B and S4C). Both inulin 
and mucin primarily increased the relative abundance of taxa mapping in or near 
Clostridium cluster XIVa (Figures 5D and 5E). Inulin specifically induced six phylotypes 
related to Bacteroides spp. (primarily Bacteroides acidifaciens), three phylotypes related to 
Barnesiella spp., and a group related to Parasutterella excrementihominis, the latter of which 
was not detected following mucin treatment. Inulin also increased the relative abundance of 
three phylotype groups related to Bifidobacterium spp., whereas only one group was induced 
by mucin. The genomes of Bacteroides, Bifidobacterium, and Barnesiella spp. encode 
numerous glycosyl hydrolase activities (http://www.cazy.org/) that support cross-feeding 
interactions with sugar-fermenting bacteria, particularly Clostridiales spp.
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Mice treated with doses of MEKi alone that effectively controlled subcutaneously implanted 
MaN-RAS1 tumor growth in syngeneic C57BL/6 mice showed enrichment of 14 phylotype 
groups in the gut microbiota, none of which negatively correlated with tumor size (Table 
S3). Analysis of taxa in tumor-bearing mice fed inulin identified eight phylotype groups 
enriched in Actinobacteria, Bifidobacterium longum, and two Olsenella spp. (Table S3). 
Only one phylotype group mapping distantly to Clostridium cellobioparum was negatively 
correlated with tumor size. Mucin treatment alone resulted in an increase in the relative 
abundance of 56 phylotype groups featuring diversity of taxa, including Bacteroides, 
Parabacteroides, Olsenella, and Clostridium. Mucin uniquely increased the relative 
abundance of five Lactobacillus spp., all of which were positively correlated with tumor 
size, albeit not to the level of statistical significance. Mucin feeding may thus induce an 
imbalance between enrichment of phylotypes that correlated positively versus negatively 
with tumor size, resulting in a failure to control tumor growth (Table S3).
MEKi co-administration altered the relative abundance of 21 phylotype groups (5 increased) 
in inulin-treated mice and of 15 phylotype groups (6 increased) in mucin-treated mice at 
sacrifice (Table S3). Analysis of the phylotypes in inulin+MEKi-treated mice compared with 
inulin-treated mice revealed four groups that negatively correlated with tumor size, based on 
relative abundance at sacrifice (Figure 5F). Of these, Akkermansia muciniphila was robustly 
enriched, together with Actinobacteria, Bifidobacterium longum, Olsenella profusa, and 
Parvibacter caecicola. Akkermansia muciniphila has previously been demonstrated to 
possess anti-tumor properties (Routy et al., 2018). Because Akkermansia muciniphila was 
also induced in mucin+MEKi-treated mice, enrichment of this phylotype may be insufficient 
to control MaN-RAS tumor growth. Rather, interactions between other inulin-induced taxa 
may be required for Akkermansia muciniphila to promote the anti-tumor phenotype. The 
four phylotype groups that were enriched in mucin+MEKi-treated mice compared with 
mucin-treated mice, and that negatively correlated with tumor size, may be involved in 
mucin-promoted control of tumor growth (Figure 5G).
Meta-analysis of Anti-tumor Microbiota
Studies of microbiota-mediated control of tumor growth have largely focused on a single or 
small group of bacterial species and/or species that are over-represented in mice or humans 
and are positively associated with control of tumor growth. However, in the present study, 
we detected negative correlations between tumor size and the abundance of multiple 
phylogenetic clades (Figure 6), which has been difficult to reconcile with earlier studies. 
Some bacterial strains identified here have not previously been described to be associated 
with anti-tumor immunity. In addition to Bifidobacteria, Bacteroides, Barnesiella, and 
Parabacteroides (Daillère et al., 2016; Matson et al., 2018; Sivan et al., 2015; Tanoue et al., 
2019; Vétizou et al., 2015), which have been implicated in anti-tumor responses, we 
identified Olsenella, Prevotellamassilia, and Culturomica as additional taxa whose 
abundance correlates with tumor size. Six members of the Firmicutes phylum, including taxa 
mapping in or near Clostridium cluster XIVa, were also associated with tumor growth 
inhibition (Figure 6).
Li et al. Page 8
Cell Rep. Author manuscript; available in PMC 2020 March 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Short-Chain Fatty Acids Are Not Sufficient to Attenuate Tumor Growth
Among the taxa enriched in gut microbiota of prebiotic-fed mice that control tumor growth 
are many that mapped in or near Clostridium cluster XIVa, which includes butyrate-
producing species. We therefore next tested the effect on tumor growth of individual or 
combinations of the short-chain fatty acids (SCFAs) butyrate, propionate, and acetate (150 
mM alone or 50 mM each in combination) administered in the drinking water starting 2 
weeks before melanoma cell injection and for the duration of the experiment thereafter. 
None of the SCFAs, alone or in combination, reduced the tumor burden (Figure S5A), 
suggesting that production of SCFAs alone is insufficient to affect tumor growth.
Mucin-Induced Tumor Control Depends on Gut Microbiota
To verify the dependency of prebiotic-induced tumor control on gut microbiota, a minimal 
microbiota (altered Schaedler flora [ASF]) was allowed to colonize GF C3H/HeN mice for 2 
weeks to induce immune maturation, and then the mice were initiated on mucin treatment 
for 2 weeks before injection of subcutaneously transplanted N-Ras mutant SW1 tumor cells. 
In these mice, mucin treatment failed to attenuate SW1 tumor growth (Figure S5B), 
indicating that mucin-promoted tumor growth control depends on specific gut microbiota. 
These observations are consistent with our previous demonstration that transfer of feces 
from Rnf5−/− mice, which harbor microbiota that can limit tumor growth, to WT GF mice 
elicited an effective anti-melanoma response (Li et al., 2019b).
Mucin and Inulin Treatment Leads to Activation of DCs and T Cells
To further explore the mechanism of action of mucin and inulin on the anti-tumor immune 
response, we treated murine bone marrow-derived DCs (BMDCs) for 24 h in vitro with 
mucin or inulin (0.05 or 0.5 mg/mL). As shown in Figure S5C, expression of the DC 
activation markers CD40 and CD80, as well as MHC class I and MHC class II, was 
increased by mucin treatment, but not inulin treatment. In contrast, in vitro treatment of 
CD8+ T cells isolated from the spleens of C57BL/6 mice revealed that whereas mucin had a 
limited effect on T cell activation (Figure S5D), inulin treatment increased the production of 
cytokines, chemokines, and the cytotoxic effector protein granzyme B (Figure S5D). These 
results suggest that inulin and mucin differentially affect the expression of genes involved in 
activation of antigen-presenting and/or effector functions of DCs and T cells. Given that 
mucin failed to elicit anti-tumor immunity and tumor growth inhibition in GF mice, we 
speculate that the effects of mucin and inulin detected in vitro would likely be secondary to 
the effects of prebiotics on the microbiota in vivo (Figure S5B).
Mucin and Inulin Promote Proinflammatory Gene Expression in Intestinal Epithelial Cells 
In Vivo
We next determined the effect of mucin and inulin on gene expression by intestinal epithelial 
cells (IECs), which have been implicated in the activation of DCs and T cells in vivo (Wang 
et al., 2003). After treatment of WT C57BL/6 with inulin or mucin for 2 weeks, IECs were 
isolated from the small intestine and were examined for expression of immune-related 
cytokines and chemokines. IECs from inulin- or mucin-treated mice exhibited enhanced 
expression of select genes; thus, although tumor necrosis factor alpha (TNF-α) mRNA 
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levels were elevated in IECs from mucin-treated mice, NOD2, IL-6, and CXCL2 mRNA 
were increased in IECs from inulin-treated mice (Figure S5E). These findings suggest that 
inulin and mucin differentially enhance the transcription of key immune-activating cytokines 
and chemokines in IECs, providing a potential mechanism by which alterations of the gut 
microbiota may elicit anti-tumor immunity.
Prebiotic Therapy Does Not Augment the Efficacy of Anti-PD-1 Immune Checkpoint 
Therapy of Cold Melanomas
We next asked whether prebiotic treatment can enhance the efficacy of anti-PD-1 antibody, a 
commonly used immune checkpoint therapy. YUMM1.5, the BRAF mutant mouse 
melanoma cell line, is considered a cold tumor, that is, poorly responsive to immune 
checkpoint therapy (Haanen, 2017; Meeth et al., 2016). Administration of anti-PD-1 or the 
prebiotics reduced the growth of YUMM1.5 tumors in C57BL/6 mice. However, 
combination treatment with anti-PD-1 plus either inulin or mucin did not further attenuate 
tumor growth (Figures 7A and 7B), implying that anti-PD-1 and prebiotic therapy may elicit 
similar or overlapping changes in the immune system.
Mucin and Inulin Effects on Melanoma Growth Are Context Dependent
To determine whether mucin and inulin in combination have additive or synergistic effects 
on melanoma growth, we employed two models. In the first, the growth of syngeneic SW1 
NRAS mutant melanoma tumors that were subcutaneously transplanted in the syngeneic 
C3H/HeOuJ mice was attenuated by mucin treatment alone, a response that was enhanced 
by co-administration of mucin and inulin (Figure 7C). In contrast, growth of YUMM1.5 
BRAF mutant melanoma tumors that were subcutaneously transplanted in the syngeneic 
C57BL/6 mice was reduced by treatment with either mucin or inulin alone, but they did not 
have an additive effect (Figure S6). These findings suggest that tumor genotypes and/or 
mouse strains affect the ability of prebiotics to attenuate tumor growth, further illustrating 
the complexity of the mechanisms by which gut microbiota impacts the anti-tumor 
phenotype.
DISCUSSION
In this study, we have demonstrated, using subcutaneously implanted tumors, that inulin and 
mucin induce anti-tumor immunity and concomitantly control tumor growth in syngeneic 
mouse models. The prebiotic effects depended on changes in the composition of gut 
microbiota, as illustrated by the failure of mucin to induce anti-tumor immunity in 
gnotobiotic mice harboring a minimal ASF community. In turn, changes in gut microbiota 
resulted in enhanced expression of select chemokines and cytokines in IECs, which have 
known roles in the activation of DCs and T cells (Belkaid and Hand, 2014; Chistiakov et al., 
2015). As a result, the growth of melanoma and/or colon cancer was attenuated, 
accompanied by increased infiltration of effector T cells and DCs and increased expression 
of immune-related genes, including chemokines and Toll-like receptor (TLRs). Notably, our 
studies were limited to subcutaneously implanted melanoma or colon cancer cell lines in two 
syngeneic mouse strains (C57BL/6 and C3H) to capture the inherent immune response. 
Thus, our studies did not address the complex nature of human tumors, which would be 
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achieved using patient-derived xenografts that lack intact immune response unless carried 
out in humanized mouse models, and they did not examine the effect of the prebiotics 
studied here in genetically engineered mouse models, which could have also allowed 
monitoring of the effect of these prebiotics at different phases of tumor evolution and in the 
proper microenvironment. Heterogenous phenotypes, of both tumors and hosts, are likely to 
best represent the heterogeneity found in man, for which corresponding models are urgently 
needed.
We found that both inulin and mucin effectively limited the growth of melanoma cells, but 
they elicited distinct phenotypes that are likely to stem from their differential effects on gut 
microbiota. For example, growth of KRAS mutant MC-38 colon cancer cells was inhibited 
by inulin, but not by mucin. In addition, inulin combined with MEKi, but not mucin, was 
able to attenuate the MEKi resistance of NRAS melanoma. These data suggest that mucin 
and inulin elicit distinct changes in gut microbiota, which then elicit anti-tumor immunity 
via different mechanisms. Our results are consistent with earlier findings that inulin can 
inhibit tumor growth (Mauro et al., 2013; Taper and Roberfroid, 1999), although the 
underlying mechanism of action remained largely unexplored.
Inulin and mucin shared a common ability to promote substantial alterations in the 
composition of fecal microbiota, leading to increases in the relative abundance of multiple 
bacterial phylotypes. We observed a negative correlation between the tumor size and a 
subset of these phylotypes, many of which have been reported to have anti-tumor potential 
in independent studies. Among those are Bifidobacterium (Matson et al., 2018; Sivan et al., 
2015), Bacteroides (Li et al., 2019b; Vétizou et al., 2015), Parabacteroides (Daillère et al., 
2016; Li et al., 2019b), Akkermansia muciniphila (Routy et al., 2018), and Barnesiella 
(Daillère et al., 2016). These taxa were enriched following prebiotic feeding and MEKi 
treatment, pointing to their possible role in mediating tumor control. We previously observed 
elevated expression and post-translational modification of mucin in Rnf5−/−mice, which 
exhibit strong anti-tumor immunity, although the change in mucin expression was not 
accompanied by alterations in mucus thickness or intestinal leakiness (Li et al., 2019b; data 
not shown). Thus, modification of mucin may be one facet of crosstalk between the gut 
microbiota and the immune system that contributes to the anti-tumor phenotype.
Among the phylotypes induced by inulin and mucin are taxa in the butyrate-producing 
Clostridium cluster XIVa. This result is consistent with an earlier report demonstrating that 
over-representation of three butyrate-producing taxa was strongly associated with 
responsiveness to ipilimumab in human melanoma patients (Chaput et al., 2017). However, 
we found that butyrate, propionate, and acetate, alone or in combination, had no effect on 
melanoma growth, suggesting that production of other SCFAs or microbial products may 
mediate this microbiota-driven anti-tumor response.
Increasing attention is being paid to the effects of MEKi, which target a signaling pathway 
often deregulated in tumors, on immune system components (Sanlorenzo et al., 2018; Yue et 
al., 2018). MEKi has been shown to impede the growth of tumors in mice while 
concomitantly promoting the effector phenotype and longevity of tumor-infiltrating CD8+ T 
cells (Ebert et al., 2016). Furthermore, MEKi can promote tumor immunogenicity in 
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preclinical models of triple-negative breast cancer, in which MEKi in combination with 
either anti-4–1BB or anti-OX-40 agonist antibodies resulted in superior therapeutic efficacy 
(Dushyanthen et al., 2017). MEKi is also capable of promoting the maturation of DCs, as 
reflected by enhanced antigen uptake, processing, and cross-presentation to T cells (Vella et 
al., 2014). Despite effective tumor inhibition by MEKi, resistance to these inhibitors 
invariably occurs (Brighton et al., 2018; Fedele et al., 2018). Here, we demonstrated that co-
administration of inulin reduces the resistance of melanoma to MEKi, pointing to the 
possible consideration of prebiotics as a means to limit therapy resistance, which remains a 
crucial unmet clinical need.
Several lines of evidence support the ability of microbiota to enhance the effectiveness of 
chemotherapy, radiotherapy, and immunotherapy (Alexander et al., 2017; Iida et al., 2013; 
Roy and Trinchieri, 2017). However, more recent studies have shown that antibiotic 
treatment or select enrichment of gut microbiota taxa can also limit the effectiveness of 
immune checkpoint therapy (Gopalakrishnan et al., 2018a, 2018b; Pitt et al., 2016). Thus, 
our finding that inulin and mucin are as effective as anti-PD-1 immune checkpoint therapy in 
limiting cold melanoma growth suggests that these prebiotics do not impede but possibly 
affect the same pathways as anti-PD-1 therapy. Combination treatment with inulin and 
mucin had an additive effect on the growth of NRAS mutant SW1 melanoma in C3H/ 
HeOuJ mice, but not on the growth of YUMM1.5 BRAF mutant melanoma in C57BL/6 
mice, further illustrating that the effective cooperation between prebiotics depends on both 
tumor and genetic background.
Collectively, the results of this study advances our understanding of tumor growth control by 
gut microbiota, demonstrating that taxa from multiple unrelated phylogenetic groups share 
the capacity to induce anti-tumor immunity. It is expected that refinement of the specific 
bacterial strains and metabolites that mediate these phenotypes will not only advance our 
understanding of the phenomenon but also facilitate the development of therapeutic 
modalities that could be tested across species.
STAR★METHODS
Detailed methods are provided in the online version of this paper and include the following:
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for reagents should be directed to and will be fulfilled by 
the Lead contact, Ze’ev Ronai, at zeev@ronailab.net. All reagents generated in this study are 
available from the Lead Contact with a completed Materials Transfer Agreement.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals and tumor model—All experimental animal procedures were approved by the 
Institutional Animal Care and Use Committee of Sanford Burnham Prebys Medical 
Discovery Institute (SBP: approval #13–130, 16–028, and 17–001) and complied with all 
relevant ethical regulations for animal testing and research. C57BL/6 mice were obtained 
from SBP. OT-I mice were obtained from SBP and crossed to CD45.1+ B6.SJLB6.SJL-
Ptprca Pepcb/BoyJ mice (Jackson Laboratories). C3H/HeOuJ mice were purchased from 
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Jackson Laboratories. Male 6–8-week-old mice were used for all experiments. GF ASF-
bearing C3H/HeN mice were bred and maintained at the University of Nebraska-Lincoln 
(UNL) Gnotobiotic Mouse Facility under gnotobiotic conditions in flexible film isolators. 
Experiments involving GF and gnotobiotic mice were approved by the Institutional Animal 
Care and Use Committee at UNL (protocol #1534). All mice were fed an autoclaved chow 
diet ad libitum (LabDiet 5K67, Purina Foods). GF status was routinely checked as 
previously described (Gomes-Neto et al., 2017). Briefly, fresh feces were collected and 
analyzed by bacterial 16S rRNA gene-specific PCR (30 cycles, universal bacteria primers 8F 
and 1391R) in combination with aerobic and anaerobic culture of feces in Brain Heart 
Infusion, Wilkins–Chalgren, and Yeast Mold broths, and on Tryptic Soy Agar plates (all 
media from Difco Becton Dickinson) at 37°C for 7 days. ASF colonization status was 
verified by qPCR analysis of fecal samples as previously described (Li et al., 2019b). 
Briefly, genomic DNA was extracted from fecal samples and ASF bacteria were quantified 
by qPCR with species-specific primers.
For tumor growth experiments, mice were injected subcutaneously (s.c.) with 1 × 106 tumor 
cells. Tumor size was measured twice a week for calculation of tumor volume. Tumors were 
weighed at the time of excision. Mouse selection for experiments was not formally 
randomized or blinded.
Cell lines—BrafV600E/+;Pten−/−;Cdkn2a−/− mouse melanoma cell line YUMM1.5 (Meeth 
et al., 2016), MC-38 cells ((Hampton et al., 2000); provided by M Karin, UCSD), MaN-
RASQ61K mouse melanoma cells ((Petit et al., 2019); Provided by Lionel Larue, CNRS) 
SW1 mouse melanoma cells ((Bhoumik et al., 2002); provided by M Kripke, MDACC) B16-
OVA ((Bellone et al., 2000); Provided by L Bradley SBP). Cell lines were maintained in 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS) and 
antibiotics. All cell lines were free of mycoplasma and were authenticated by SBP genomic 
core service.
Bacterial strains and anaerobic fecal cultures—ASF (Altered Schaedler Flora) 
consisted of the following eight isolates: ASF 356, Clostridium sp.; ASF 360, Lactobacillus 
intestinalis; ASF 361, Lactobacillus murinus; ASF 457, Mucispirillum schaedleri; ASF 492, 
Eubacterium plexicaudatum; ASF 500, Pseudoflavonifractor sp.; ASF 502, Clostridium sp.; 
and ASF 519, Parabacteroides goldsteinii. Stool collected from 12 healthy vegetarian 
volunteers or WT mice (approximately 106 cells) were inoculated into chemically defined 
medium (CDM) alone or supplemented with 1% inulin or 1% porcine gastric mucin in 
Hungate tubes. Anaerobic cultures (9% H2, 81% N2) were grown statically for 3–4 days at 
3°C to approximate saturation.
METHOD DETAILS
Chemically defined medium (CDM)—CDM contained 50 mM HEPES, 2.2 mM 
KH2PO4, 10 mM Na2HPO4, 60 mM NaHCO3; 4 mM of each amino acid except leucine 
(15 mM); 10 mL ATCC Trace Mineral Supplement; nucleoside bases (100 mg/L) inosine, 
xanthine, adenine, guanine, cytosine, thymi-dine, and uracil (400 mg/L); choline (100 
mg/L), ascorbic acid (500 mg/L), lipoic acid (2 mg/L), hemin (1.2 mg/L), and myo-inositol 
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(400 mg/L). Resazurin (1 mg/L) was added to visually monitor dissolved oxygen. The pH 
was adjusted to 7.4.
Bacterial DNA extraction and 16S library preparation—Gut microbiota in the 
mouse reach a stable homeostatic state at about 8 weeks of age (Laukens et al., 2016). Fecal 
pellets from mice ≥ 8 weeks of age were frozen on dry ice and stored at −80°C. Bacterial 
DNA was extracted using a QIAmp Fast DNA Stool Mini Kit (QIAGEN) with an additional 
5-min bead-beating step using a Mini-Beadbeater-16 (Biospec Products, OK, USA). Library 
preparation for the Illumina MiSeq platform was performed by amplification of the V3-V4 
region of the bacterial 16S ribosomal DNA gene using forward primer: 5′-
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG and 
reverse primer: 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG 
GACTACHVGGGTATCTAATCC. Adaptor and barcode sequences for dual indices were 
used as described by Illumina. PCR cleanup steps were performed using a QIAquick 96-
PCR Cleanup Kit (QIAGEN, Germany), and library quantification was performed using a 
KAPA Library Quantification Kit for Illumina platforms (KAPA Biosystems, MA, USA). 
An Experion Automated Gel Electrophoresis System (Bio-Rad, CA, USA) was used to 
measure the DNA concentration and purity in the pooled libraries. The 16S libraries were 
sequenced at Novagene (Beijing, China) and at the SBP sequencing core.
16S sequencing data processing—The original FASTQ files from Illumina 250 base-
pair paired-end sequencing were processed using a 16S amplicon sequencing pipeline 
HiMap (http://github.com/taolonglab/himap; BioRxiv 565572). The output of HiMap is 
Operational Strain Unit (OSU) which contains one or more bacterial strains that best match 
the 16S sequence and cannot be further distinguished. The percentage similarity between the 
16S sequence and the aligned region of 16S rRNA genes of the strains in the OSU is 
indicated. OSUs mapped to the same strains are grouped together (adding read counts) if 
percentage similarities are within 3%. Read counts are converted into relative abundance as 
described in HiMap. Log10-transformed relative abundances were used for comparisons 
between samples under different experimental conditions. The raw 16S sequencing data is 
available as BioProject PRJNA593851 online at: https://www.ncbi.nlm.nih.gov/bioproject/
PRJNA593851.
Taxa selection—Taxa that distinguished microbiota of inulin- or mucin-treated mice from 
control mice were selected into three sets as follows. (1) Taxa induced by inulin or mucin 
were selected by performing a paired one-tail Wilcoxon rank-sum test on the log10-
transformed relative abundances of all OSU groups in mice treated with prebiotics at time 
point B (after the start of prebiotic treatment and before tumor injection) compared with 
time point A (before prebiotic treatment) with abundance at time point B greater than time 
point A. Taxa with p values less than 0.05 were selected as set 1. (2) A similar selection to 
(1) was made for data from the control mice. Taxa with p values less than 0.2 were selected 
as set 2. This set contains taxa that were induced in the control group from time point A to 
time point B. (3) The third set of OSU groups were selected by calculating Spearman’s 
correlations between each of the OSU groups and tumor size at time point B, and selecting 
groups with p values less than 0.1. The final set of inulin- or mucin-induced taxa was 
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selected as the difference between set 1 and set 2 intersected with set 3. These are the taxa 
induced in inulin- or mucin-treated mice, but not in control mice, and had relative 
abundances before tumor injection that negatively correlated with tumor size at tumor 
collection. For analysis of mice treated with MEKi in combination with prebiotics, OSU 
groups in the fecal samples of mice treated with prebiotics alone or in combination with 
MEKi were compared at time point D (final time point before tumor collection) with 
unpaired two-sided Wilcoxon rank-sum test. OSU groups with p values less than 0.05 were 
selected for calculating Spearman’s correlations with tumor size at time point D. The OSU 
groups with correlation p values less than 0.1 were selected as the differential taxa that were 
negatively correlated with tumor size.
Tumor digestion—Tumors were excised, minced, and digested with 1 μg/mL collagenase 
D (Roche) and 100 μg/mL DNase I (Sigma) at 37°C for 1 h. Digests were then passed 
through a 70-μm cell strainer to generate a single-cell suspension. The cells were washed 
twice with PBS containing 2 mM EDTA and then stained for flow cytometry.
Flow cytometry—Tumor-derived single-cell suspensions were washed twice with FACS 
staining buffer, fixed for 15 min with 1% formaldehyde in PBS, washed twice, and 
resuspended in FACS staining buffer. For intracellular cytokine staining, cells were 
resuspended in complete RPMI-1640 (containing 10 mM HEPES, 1% non-essential amino 
acids and L-glutamine, 1 mM sodium pyruvate, 10% heat-inactivated FBS, and antibiotics) 
supplemented with 50 U/mL IL-2 (NCI) and 1 mg/mL brefeldin A (BFA, Sigma), and then 
incubated with phorbol myristate acetate (10 ng/mL) and ionomycin (0.5 μg/mL) at 37°C. 
The cells were fixed and permeabilized using a Cytofix/Cytoperm Kit (BD Biosciences) 
before staining. Antibodies to the following proteins were used: CD45.2 (104), CD8α (53–
6.7), CD4 (GK1.5), CD44 (IM7), TNF-α (MP6-XT22), IFN-γ (XMG1.2), CD11c (N418), 
CD11b (M1/70), MHC class II (M5/114.15.2), PDCA (129c1), and B220 (RA3–6B2) (all 
from BioLegend), IL-2 (JES6–5H4) and MHC class I (AF6–88.5.5.3) (both from 
eBioscience). All data were collected on an LSRFortessa (BD Biosciences) and analyzed 
using FlowJo Software (Tree Star).
Mucin and inulin treatment—For mucin treatment, C57BL/6, C3H/HeOuJ or GF ASF-
bearing C3H/HeN mice (male, 6~8 weeks old) were provided with drinking water with or 
without 3% mucin (Lee Biosolutions) starting 14 days before tumor inoculation. Water was 
changed every other day. For inulin treatment, C57BL/6 or C3H/HeOuJ mice (male, 6~8 
weeks old) received standard chow (TD. 94048, AIN-93M, Purified Diet, ENVIGO), 
standard chow enriched with long-chain inulin by substituting all sucrose and 5% of corn 
starch, or a modified chow (TD. 160256, Modified AIN-93M, Diet with 15% inulin, 
ENVIGO) starting 14 days before tumor inoculation. Chow was refreshed two times a week.
RNA extraction and qRT-PCR analysis—Total RNA was extracted from tumor 
samples using an RNeasy Fibrous Tissue Midi Kit (QIAGEN) or from cells using a High 
Capacity Reverse Transcriptase Kit (Invitrogen), according to the manufacturers’ protocols. 
Purity and concentration of extracted RNA were determined by reading at 260 and 280 nm 
in a NanoDrop spectrophotometer (Thermo Fisher). qRT-PCR analysis was performed using 
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a SYBR Green RT-PCR Kit (Invitrogen) on a Bio-Rad CFX Connect Real-Time system. 
Expression levels were normalized to 18S or Tubb5 levels. The sequence-specific primers 
used in this study are shown in Table S4.
BMDCs—BM cells were isolated from the tibiae and femurs of C57BL/6 mice and cultured 
in DMEM medium containing 10% FBS, 1% penicillin/streptomycin, and recombinant 
mouse GM-CSF (20 ng/mL; BioLegend) for 8 days at 37°C.
Isolation of IECs—A 10-cm section of mouse small intestine was opened longitudinally, 
minced, washed in 150 mM NaCl containing 1 mM DTT, and then resuspended in 
dissociation buffer (130 mM NaCl, 10 mM EDTA, 10 mM HEPES [pH 7.4], 10% FCS, and 
1 mM DTT). The sections were incubated at 37°C for 30 min with vigorous shaking to 
release the IECs from the lamina propria. The IEC suspension was then carefully aspirated, 
centrifuged, and washed in ice-cold PBS.
Serum cytokine and chemokine detection—Serum cytokines and chemokines were 
quantified using the LEGENDplex™ mouse inflammation panel and mouse 
proinflammatory chemokine panel (BioLegend), respectively. All data were collected on an 
LSRFortessa and analyzed using LEGENDplex™ software (BioLegend).
In vivo antibody treatments—Mice were injected i.p. with 200 μg anti-PD-1 (clone 
RMP1–14) or rat IgG2a isotype control on days 7, 10, 13, and 16 after tumor inoculation. 
All mAbs for in vivo use were GoInVivo grade from BioLegend. CD4+ and CD8+ T cells 
were depleted by i.p. injection of 400 μg anti-mouse Thy1.2 (CD90.2, clone 30H12 from 
Bio X Cell) or rat IgG2b isotype control. Antibodies were injected two times a week starting 
on day 3 after tumor inoculation. The efficacy of depletion was assessed by FACS analysis 
of blood samples collected on day 8 after tumor inoculation.
In vivo OT-I T cell proliferation assay—CD8+ T cells were isolated from the spleens of 
naive OT-I CD45.1+ mice, labeled with CFSE, and injected i.v. into WT CD45.2+ C57BL/6 
mice treated with or without mucin. After 24 h, the mice were injected s.c. with 1 × 106 
B16-OVA melanoma cells. Seven days later, the spleen, tumor-draining lymph nodes, and 
non-draining lymph nodes were harvested and analyzed by flow cytometry. The proliferation 
of OT-1 CD8+ T cells was assessed by analysis of CFSE dilution within the population by 
gating on CD45.1+ CD8+ T cells.
CD8+ T cell enrichment—CD8+ T cells were enriched by negative selection (StemCell 
Technologies, Inc.) according to the manufacturer’s instruction from spleens of C57BL/6 
mice that were untreated or treated with mucin or inulin for 2 weeks. Briefly, the enrichment 
of mouse CD8+ naive T cells utilized a biotinylated antibody cocktail (Biotinylated CD4, 
CD11b, CD11C, CD19, CD24 and B220 antibodies) that were captured on streptavidin-
coated magnetic beads. Pre-incubation of cells with the antibody cocktail-bound magnetic 
beads enriched the CD8+ T cells in solution. The purity of the enriched CD8+ T was 
confirmed by flow cytometry (> 95%). FACS analysis was performed using FlowJo 
software.
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QUANTIFICATION AND STATISTICAL ANALYSIS
Unless otherwise noted, all data are shown as the mean ± s.e.m. Before statistical analysis, 
data were subjected to the Kolmogorov– Smirnov test to determine distribution. Variance 
similarity was tested using an F test for two groups and Bartlett’s test for multiple groups. 
Two groups were compared using the two-tailed t test for parametric data or the Mann–
Whitney U test for non-parametric data. Multiple groups were compared using one-way 
ANOVA with Tukey’s, Dunnett’s, or Bonferroni’s correction for parametric data or using the 
Kruskal–Wallis test with Dunn’s correction for non-parametric data. Tumor growth curves 
were analyzed using two-way ANOVA with Sidak’s, Tukey’s, or Bonferroni’s correction for 
multiple comparisons. Statistical details of each experiment are indicated in the 
corresponding figure legends.
DATA AND CODE AVAILABILITY
The approach used to map microbiota taxa (Figures 5, 6, and S4) is detailed at: http://
github.com/taolonglab/himap; BioRxiv 565572. The microbiome sequence data used for 
mapping the microbiota taxa have been deposited in NCI BioProject: PRJNA593851 https://
www.ncbi.nlm.nih.gov/bioproject/PRJNA593851. The raw data of this manuscript was 
deposited online in the Mendeley archive https://data.mendeley.com/datasets/zrjr39f7mb/
draft?a=28ed04b4-6d90-4eec-be59-c42e05589ade.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Mucin and inulin, prebiotics, inhibit melanoma growth in syngeneic mouse 
models
• Changes in gut microbiota taxa by these prebiotics induce anti-tumor 
immunity
• Inulin attenuates melanoma resistance to MEKi in a mouse melanoma model
• Inulin and mucin elicit distinct microbiota changes and an additive effect in 
select models
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Figure 1. Administration of Mucin or Inulin Reduces Tumor Growth and Induces Anti-tumor 
Immunity
(A) Growth of YUMM1.5 tumors that were subcutaneously transplanted in syngeneic 
C57BL/6 mice. Mice were provided with a control diet, 3% mucin in drinking water, or 15% 
inulin-supplemented chow starting 14 days before tumor inoculation (control, n = 12; mucin, 
n = 15; inulin, n = 15).
(B) Quantification of tumor-infiltrating total CD45+ cells and effector (CD44hi) CD4+ or 
CD8+ T cells from mice treated as in (A) (control, n = 9; mucin, n = 10; inulin, n = 10).
(C) Quantification of tumor-infiltrating, IFN-γ-producing CD4+ T cells from mice treated as 
in (A) (n = 10).
(D) Quantification of tumor-infiltrating total DCs and DC subsets in mice treated as in (A) 
(control, n = 9; mucin, n = 10; inulin, n = 10).
(E) MFI of MHC class I and MHC class II on tumor-infiltrating DCs in mice treated as in 
(A) (control, n = 9; mucin, n = 10; inulin, n = 10).
(F) Wild-type C57BL/6 mice (n = 12) were fed control or 15% inulin-supplemented chow 
starting 14 days before subcutaneous (s.c.) injection of YUMM1.5 melanoma cells (1 × 
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106). Anti-mouse Thy1.2 or control immunoglobulin G (IgG, 400 μg) were injected two 
times a week starting 3 days after tumor inoculation (n = 12). Tumor volume was assessed 
two times a week. FACS analysis revealed >90% depletion of blood CD4+ and CD8+ T cells 
on day 8 after tumor inoculation. Data are representative of three independent experiments 
(A–E) or one experiment (F). Graphs show the mean ± SEM. *p < 0.05, **p < 0.005, ***p < 
0.001, ****p < 0.0001 by two-way ANOVA with Bonferroni’s correction (A and F) or by 
one-way ANOVA with Bonferroni’s correction (B–E).
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Figure 2. Mucin and Inulin Induce Enhanced Expression of Immunoregulatory Genes in Tumors
(A) qPCR analysis of immune-related genes in subcutaneously transplanted melanoma 
grown in syngeneic C57BL/6 mice that received a control diet, 3% mucin in drinking water, 
or 15% inulin-supplemented chow starting 14 days before tumor inoculation (n = 6).
(B) Quantification of CD45.1+ OT-I CD8+ T cells in the tumor-draining lymph nodes 
(TdLN) and non-draining lymph nodes (ndLN) of C57BL/6 mice (CD45.2+) treated with or 
without mucin and injected with B16-OVA melanoma cells (TdLN, n = 7; ndLN, n = 8). 
Right dot plots show gating of CD45.1+ CD8+ cells.
(C) Serum cytokine and chemokine levels in naive WT mice treated with or without mucin 
(n = 10).
(D) Serum cytokines in WT mice treated with or without mucin on day 10 after tumor 
inoculation (n = 10).
Data are representative of three independent experiments (A and B) or one experiment (C 
and D). Graphs show the mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0.001, ****p < 
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0.0001 by one-way ANOVA with Tukey’s correction (A) or by two-tailed t test or Mann-
Whitney U test (B–D).
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Figure 3. Mucin and Inulin Modulate the Composition and Diversity of Gut Microbiota
(A and B) Principal-component analysis of all taxa enumerated in fecal microbiota of 
control and mucin-treated (A) or inulin-treated (B) C57BL/6 mice, examined before 
prebiotic treatment, before subcutaneous injection of syngeneic YUMM1.5 tumor cells, and 
before tumor collection (control, n = 12; mucin, n = 15; inulin, n = 15).
(C) Time course of the relative abundance of the six taxa enriched in inulin-treated mice that 
negatively correlate with YUMM1.5 tumor size (control, n = 12; inulin, n = 15). Time points 
are before inulin treatment, before tumor injection, and before tumor collection.
Data are representative of two independent experiments.
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Figure 4. Inulin Controls Colon Cancer Growth and Induces Anti-tumor Immunity
(A) Growth of MC-38 mouse colorectal cancer cells (1 × 106) injected subcutaneously into 
syngeneic C57BL/6 mice that received control diet, 3% mucin in drinking water, or 15% 
inulin-supplemented chow starting 14 days before tumor inoculation (control, n = 9; mucin, 
n = 15; inulin, n = 15).
(B) MFI of MHC class II and MHC class I in MC-38 tumor-infiltrating DCs (n = 8).
(C) Boxplot of the relative abundance of the taxa enriched in inulin-treated mice and 
positively correlated with tumor size (n = 10).
Data are representative of two independent experiments. Graphs show the mean ± SEM. *p 
< 0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001 by one-way ANOVA with Bonferroni’s 
correction (B) or by two-way ANOVA with Tukey’s correction (A).
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Figure 5. Inulin Supplementation Overcomes Melanoma Resistance to MEKi
(A) Growth of NRASQ61K mouse melanoma cells (1 × 106) (control, n = 11; mucin, n = 9; 
inulin, n = 9; MEKi, n = 10; MEKi+mucin, n = 8; MEKi+inulin, n = 10) that were 
subcutaneously transplanted in syngeneic C57BL/6 mice that received control diet, 3% 
mucin in drinking water, or 15% inulin-supplemented chow starting 14 days before tumor 
inoculation. When tumors reached a volume of 10–20 mm2, mice were administered MEKi 
(PD325901, 10 mg/kg) once daily by gavage. Tumor volume was assessed every 4 days.
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(B) Number of tumor-infiltrating effector (CD44hi) CD4+ and CD8+ T cells and total CD45+ 
cells per tumor weight (in grams) in mice treated as in (A) (MEKi, n = 7; MEKi+mucin, n = 
8; MEKi+inulin, n = 8).
(C) Number of tumor-infiltrating DCs and DC subsets per tumor weight (in grams) and 
expression of MHC class I on DCs in mice treated as in (A) (MEKi, n = 8; MEKi+mucin, n 
= 7; MEKi+inulin, n = 8).
(D) Pie chart of taxa enriched in inulin-treated mice and negatively correlated with MaN-
RAS tumor size (n = 10).
(E) Pie chart of taxa enriched in mucin-treated mice microbiota that negatively correlate 
with MaN-RAS tumor size (n = 10).
(F) Relative abundance of taxa enriched in inulin+MEKi-treated mice and negatively 
correlated with MaN-RAS tumor size (n = 10).
(G) Relative abundance of taxa enriched in mucin+MEKi-treated mice and negatively 
correlated with MaN-RAS tumor size (n = 10).
Data are representative of two independent experiments. Graphs show the mean ± SEM. *p 
< 0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001 by one-way ANOVA with Tukey’s 
correction (B and C) or by two-way ANOVA with Bonferroni’s correction (A).
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Figure 6. A Cladogram Representation of Taxa Enriched in Fecal Microbiota of Mice 
Administered Mucin or Inulin
Cladogram representation of taxa enriched in fecal microbiota of mice (control, n = 12; 
mucin, n = 15; inulin, n = 15) administered mucin (red) or inulin (blue). Data are 
representative of two independent experiments.
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Figure 7. Combination Therapy with Prebiotics and Anti-PD-1 Modulates Tumor Growth in a 
Context-Dependent Manner
(A) Growth of YUMM1.5 tumors that were subcutaneously transplanted in syngeneic 
C57BL/6 mice that were fed control chow or chow supplemented with 15% inulin starting 
14 days before tumor inoculation (control, n = 7; inulin, n = 7; PD-1, n = 10; PD-1+inulin, n 
= 9). Mice were injected with control IgG or anti-PD-1 blocking antibody on days 7, 10, 13, 
and 16 after tumor inoculation.
(B) Growth of YUMM1.5 tumors in C57BL/6 mice that received 0% or 3% mucin in 
drinking water starting 14 days before tumor inoculation (control, n = 7; mucin, n = 7; PD-1, 
n = 10; PD-1+mucin, n = 9). Mice were injected with antibodies as described in (A).
(C) Growth of SW1 mouse melanoma cells in C3H/ HeOuJ mice that received a control diet, 
3% mucin in drinking water, or 15% inulin-supplemented chow starting 14 days before 
tumor inoculation (control, n = 8; mucin, n = 8; inulin, n = 7; mucin+inulin, n = 9). Data are 
representative of two independent experiments. Graphs show the mean ± SEM. *p < 0.05, 
**p < 0.005, ***p < 0.001, ****p < 0.0001 by two-way ANOVA with Bonferroni’s 
correction.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Purified anti-mouse CD16/32 BioLegend Cat#101302; clone 93; RRID: 
AB_312800
PerCP anti-mouse CD45.2 BioLegend Cat# 109826; clone 104; 
RRID: AB_893349
Pacific Blue anti-mouse CD8a BioLegend Cat# 100725; clone 53–6.7; 
RRID: AB_493425
Brilliant Violet 605 anti-mouse CD4 BioLegend Cat# 100451; clone GK1.5; 
RRID:AB_2564591
FITC anti-mouse CD25 BioLegend Cat# 101908; clone 3C7; 
RRID: AB_961210
APC/Cy7 anti-mouse/human CD44 BioLegend Cat# 103028; clone IM7; 
RRID: AB_830785
PE/Cy7 anti-mouse TNF-α BioLegend Cat# 506324; clone MP6-
XT22; RRID: AB_2204356
APC anti-mouse IFN-γ BioLegend Cat# 505810; clone XMG1.2; 
RRID: AB_315403
APC anti-mouse CD11c BioLegend Cat# 117310; clone N418; 
RRID: AB_313778
APC anti-mouse CD103 BioLegend Cat# 121414; clone 2E7; 
RRID: AB_1227503
FITC anti-mouse H-2Kb BioLegend Cat# 116506; clone AF6–
88.5; RRID: AB_313733
Pacific Blue anti-mouse I-A/I-E BioLegend Cat# 107620; clone 
M5/114.15.2; RRID: 
AB_493527
FITC anti-mouse CD45.1 BioLegend Cat# 110706; clone A20; 
RRID: AB_313495
APC/Cy7 anti-mouse/human CD11 b BioLegend Cat# 101225; clone M1/70; 
RRID: AB_830641
PE anti-mouse CD317 (BST2, PDCA-1) BioLegend Cat#127104; clone129C1; 
RRID: AB_1953283
FITC anti-mouse/human IL-2 eBioscience Cat# 11–7021–41; clone 
JES6–5H4; RRID: 
AB_10734043
FITC anti-mouse/human MHC Class I eBioscience Cat# 11–5958–82; clone 
AF6–88.5.5.3; RRID: 
AB_11149502
PE/Cy7 anti-mouse/human CD45R/B220 BioLegend Cat# 103222; clone RA3–
6B2; RRID: AB_313005
GoInVivo Purified anti-mouse CD279 (PD-1) BioLegend Cat# 114112; clone RMP1–
14; RRID: AB_2566090
GoInVivo Purified Rat IgG2a, κ Isotype Ctrl BioLegend Cat#400560; clone RTK2758
InVivoMAb anti-mouse Thy1.2 (CD90.2) BioXCell Cat# BE0066; clone 30H12; 
AB_1107682
Bacterial and Virus Strains
ASF (Li et al., 2018) N/A
Chemicals, Peptides, and Recombinant Proteins
GM-CSF BioLegend Cat# 576306
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REAGENT or RESOURCE SOURCE IDENTIFIER
CFSE (carboxyfluorescein succinimidyl easter) Thermo Fisher 
Scientific
Cat# C34554
Collagenase D Roche Cat #11088882001
DNase Sigma Cat #DN25–1G
Brefeldin A Sigma Cat# B7651–5MG
Phorbol 12-myristate 13-acetate Sigma Cat# P8139–1MG
lonomycin calcium salt Sigma Cat# 3909–1ML
Mucin Lee 
Biosolutions
Cat# 435–10
Dulbecco’s modified Eagle’s medium (DMEM) Corning Cat# 10–013-CV
Fetal bovine serum (FBS) Gemini 
Bioproducts
Cat#900–208
Penicillin (100 units/mL) and Streptomycin (100ug/mL) Corning Cat#30–002-CI
Trypsin-EDTA (0.25%), phenol red Fisher 
Scientific
Cat#25200056
DPBS without Mg2+ and Ca2+ Corning Cat#21–031-CV
HBSS without Mg2+ and Ca2+ Corning Cat#21021152
RBC lysis buffer Sigma Cat#R7757
HEPES Buffer Corning Cat#25–060-CI
2-mercaptoethanol Sigma Cat#133051
Critical Commercial Assays
RNeasy Plus Mini Kit QIAGEN Cat#74134
LEGENDplex mouse inflammation panel BioLegend Cat#740446
LEGENDplex mouse proinflammatory chemokine panel BioLegend Cat#740451
RNeasy Fibrous Tissue Mini kit QIAGEN Cat#74704
High Capacity Reverse Transcriptase kits Invitrogen Cat#4368814
SYBR Green RT-PCR kits Invitrogen Cat#4385610
BD Cytofix/Cytoperm BD 
Biosciences
Cat#554714
QIAquick 96-PCR Cleanup kit QIAGEN Cat#28181
QIAamp Fast DNA Stool Mini Kit QIAGEN Cat#51604
Deposited Data
Bacterial 16 s sequence This paper The approach used to map 
microbiota taxa is detailed at: 
http://github.com/taolonglab/
himap; BioRxiv 565572. The 
microbiome sequence data 
have been deposited in the 
NCI BioProject: 
PRJNA593851 https://
www.ncbi.nlm.nih.gov/
bioproject/PRJNA593851
Raw data This paper The raw data were deposited 
to Mendeley https://
data.mendeley.com/datasets/
zrjr39f7mb/draft?
a=28ed04b4-6d90-4eec-be59-
c42e05589ade.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Mouse: YUMM1.5 Gift from 
Marcus 
Bosenberg 
(Meeth et al., 
2016)
N/A
Mouse: MC-38 Gift from 
Michael Karin 
(Li et al., 
2019b)
N/A
Mouse: MaN-RASQ61K Gift from 
Lionel Larue 
(Petit et al., 
2019)
N/A
Mouse: SW1 Gift from 
Margaret 
Kripke 
(Bhoumik et 
al., 2002)
N/A
Mouse: B16-OVA Gift from 
Linda Bradley 
(Li et al., 
2019b)
N/A
Experimental Models: Organisms/Strains
Mouse: C57BL/6 Sanford 
Burnham 
Prebys Medical 
Discovery 
Institute
N/A
Mouse: CD45.1 (B6.SJLB6.SJL-Ptprca Pepcb/BoyJ) The Jackson 
Laboratory
Stock No: 002014
Mouse: C3H/HeOuJ The Jackson 
Laboratory
Stock No: 000635
Mouse: EX-germ-free ASF-bearing C3H/HeN University of 
Nebraska-
Lincoln (UNL)
N/A
Oligonucleotides
qPCR primer sequences, See Table S4 This paper N/A
V3-V4 Forward primer: 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG
This paper N/A
V3-V4 Reverse primer: GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG 
GACTACHVGGGTATCTAATCC
This paper N/A
Software and Algorithms
GraphPad Prism 6 and 7 Graphpad 
Software
N/A
FlowJo v10.1 and v9.9 Treestar N/A
FACSDiva Software BD N/A
Algorithms HiMAP This paper N/A
LEGENDplexTM BioLegend N/A
Other
100 um cell strainer Thermo Fisher Cat# 22363549
Purified Diet, AIN-93M, ENVIGO TD. 94048,
Modified AIN-93M, Diet w 15% inulin, ENVIGO TD. 160256
Chow diet ad libitum (Purina Foods) LabDiet Form: 5K67
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